List of GLP-1 Agonists for Metabolic Health Support
Explore FDA-approved GLP-1 agonists and how licensed providers may use them to support metabolic health goals.
Curious about microdosing GLP-1 for wellness goals? Learn how some licensed providers approach dosing strategies and patient-centered care.
“Microdosing” is a trending concept in wellness spaces, but what does it mean when referring to GLP-1 medications? While not a recognized medical term or standardized treatment protocol, some licensed healthcare providers may explore starting GLP-1 treatment at lower-than-typical doses. This may reflect a personalized approach to care based on an individual’s preferences, medical history, and goals.
GLP-1 medications are FDA-approved for managing blood sugar in individuals with type 2 diabetes and for chronic weight management in certain patients. All prescriptions must be written by a licensed provider who determines medical appropriateness through a comprehensive review.
Eden does not provide medical care, prescribe medication, or manufacture any drug products. Our platform connects individuals with independent, licensed providers for treatment evaluation.
While not a medically defined concept, “microdosing” is sometimes used to describe initiating treatment with GLP-1 medications at a dose below the standard starting amount. This approach may be considered by a licensed provider as part of a personalized strategy to help support patient comfort during the early phases of care.
Individuals who are concerned about side effects like nausea or who are seeking a gradual start may benefit from this slower approach. However, all decisions about dosage and scheduling must be made by a licensed healthcare provider based on a comprehensive evaluation of the patient’s medical history and treatment goals.
GLP-1 medications are not intended to be one-size-fits-all. Personalized treatment approaches may include gradual dose escalation, especially when aiming to support tolerance and alignment with the patient’s preferences.
A licensed provider may:
This type of personalized care may help create a more comfortable and sustainable experience for some individuals during the early stages of GLP-1 use.
{{primary-cta}}
Before starting GLP-1 treatment, it’s important to have a transparent and informed conversation with your provider. Consider asking:
These discussions help set expectations and ensure that your plan is personalized and clinically supported from the beginning.
Eden is a digital health platform that helps individuals connect with licensed healthcare providers who evaluate eligibility for GLP-1 treatment options. Eden does not manufacture medications, prescribe treatments, or practice medicine.
If a licensed provider determines that a GLP-1 medication is medically appropriate, prescriptions are filled by independent, state-licensed pharmacies. Eden does not offer compounded or investigational medications.
Our goal is to simplify the process of accessing provider-led care by facilitating the first step, connecting with a provider you can trust.
{{primary-cta}}
Though “microdosing” is not a medically recognized term, it reflects a growing interest in personalized, comfort-focused care. Some licensed healthcare providers may choose to begin GLP-1 treatment at lower doses when medically appropriate and aligned with an individual’s needs.
Any such decisions are made solely by licensed providers after a full evaluation. A well-supported treatment journey should always include regular provider check-ins, goal alignment, and individualized care planning.
Eden helps individuals connect with licensed healthcare providers who evaluate and manage prescription treatment plans. Providers on the Eden platform determine what is medically appropriate and oversee every aspect of your care.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. No health claims are made unless supported by multiple peer-reviewed studies. Please consult a licensed healthcare provider before making any medical decisions.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Ghusn, W., & Hurtado, M. D. (2024). Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars, 12, 100127. https://doi.org/10.1016/j.obpill.2024.100127